OncoMed Doses First Patient in Phase 1b Portion of anti-TIGIT Clinical Trial
Expanded Phase of Trial will Assess anti-TIGIT in Combination with anti-PD1 REDWOOD CITY, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing …